JOURNAL ARTICLE
MULTICENTER STUDY
Add like
Add dislike
Add to saved papers

Ovarian Metastases from Breast Cancer: A Series of 28 Cases.

BACKGROUND/AIM: Ovarian metastases from breast cancer present diagnostic and therapeutic challenges. We conducted a two-center retrospective study to analyze the characteristics and evolution of patients with histologically proven ovarian metastases from breast cancer.

PATIENTS AND METHODS: The records of 28 patients were analyzed, taking into consideration clinical and biological characteristics of primary breast tumors and ovarian metastases. Moreover, the outcomes of patients after diagnosis of metastases were analyzed by comparing two patient groups defined by whether the surgical treatment of ovarian metastases was optimal (residual tumor <2 cm) or not (residual tumor >2 cm).

RESULTS: Ovarian metastases are largely found in primary breast cancer patients with poor prognostic factors (large tumor size, positive lymph nodes, high-grade) and lobular histology, occurring on average 5 years after the diagnosis of breast cancer. Their symptoms are mild and measurement of serum markers cancer antigen (CA) 125 and CA 15-3 is useful. Their prognosis is bleak due to frequent co-existence with other metastatic sites. Lobular histology of the initial breast tumor is the only significant poor prognostic factor in our study.

CONCLUSION: Women with lobular carcinoma of the breast and poor prognostic factors may benefit from ovarian surveillance based on CA 125. Following the discovery of ovarian metastases from breast cancer, further investigations are warranted to determine the extent of disease, specifically whether multiple metastases are present. Treatment of a solitary ovarian metastasis is based on surgery leaving no residual disease and adjuvant systemic treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app